Page last updated: 2024-12-07
averufanin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
averufanin: precursor of aflatoxin B1; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 119255 |
SCHEMBL ID | 15676485 |
MeSH ID | M0147075 |
Synonyms (8)
Synonym |
---|
averufanin |
28458-24-4 |
1,3,6,8-tetrahydroxy-2-[(2s,6s)-6-methyloxan-2-yl]anthracene-9,10-dione |
9,10-anthracenedione, 1,3,6,8-tetrahydroxy-2-(tetrahydro-6-methyl-2h-pyran-2-yl)-, cis-(+)- (van) |
9,10-anthracenedione, 1,3,6,8-tetrahydroxy-2-((2r,6r)-tetrahydro-6-methyl-2h-pyran-2-yl)-, rel-(+)- |
SCHEMBL15676485 |
1,3,6,8-tetrahydroxy-2-(6-methyloxan-2-yl)anthracene-9,10-dione |
DTXSID60951105 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (20.00) | 18.7374 |
1990's | 1 (20.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 2 (40.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |